Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020 [cited 2022 Oct 3];148:157–66. https://linkinghub.elsevier.com/retrieve/pii/S0167814020301845.

Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020 [cited 2022 Oct 3];21:e18–28. http://www.thelancet.com/article/S1470204519307181/fulltext.

Willmann J, Vlaskou Badra E, Adilovic S, Christ SM, Ahmadsei M, Mayinger M et al. Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease. Clin Transl Radiat Oncol. 2022 [cited 2022 Oct 3];37:12–8. http://www.ncbi.nlm.nih.gov/pubmed/36046333.

Al-Shafa F, Arifin AJ, Rodrigues GB, Palma DA, Louie AV. A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead? Front Oncol. 2019 [cited 2022 Oct 3];9:543. http://www.ncbi.nlm.nih.gov/pubmed/31293976.

Chiloiro G, Boldrini L, Romano A, Placidi L, Tran HE, Nardini M et al. Magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) for oligometastatic patients: a single-center experience. Radiol Med. 2023 [cited 2023 Apr 24]; https://pubmed.ncbi.nlm.nih.gov/37079221/.

Macchia G, Jereczek-Fossa BA, Lazzari R, Cerrotta A, Deodato F, Ippolito E et al. Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD). Int J Gynecol Cancer. 2022 [cited 2022 Oct 4];32:939–43. https://ijgc.bmj.com/content/32/7/939.

Vernaleone M, Bonomo P, Di Cataldo V, Saieva C, Masi L, Desideri I et al. Robotic stereotactic radiotherapy for liver oligometastases from colorectal cancer: a single-center experience. Radiol Med. 2019 [cited 2023 Apr 2];124:870–6. https://pubmed.ncbi.nlm.nih.gov/31104277/.

Li GJ, Arifin AJ, Al-Shafa F, Cheung P, Rodrigues GB, Palma DA et al. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions. Ann Palliat Med. 2021 [cited 2022 Oct 3];10:6045–51. https://pubmed.ncbi.nlm.nih.gov/32787370/.

Lancellotta V, Fanetti G, Monari F, Mangoni M, Mazzarotto R, Tagliaferri L et al. Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review. Radiol Med. 2022 [cited 2023 Apr 1];127:681–9. https://pubmed.ncbi.nlm.nih.gov/35394605/.

Jereczek-Fossa BA, Bortolato B, Gerardi MA, Dicuonzo S, Arienti VM, Berlinghieri S et al. Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. Radiol Med. 2019 [cited 2023 Apr 1];124:315–22. https://pubmed.ncbi.nlm.nih.gov/30554376/.

Dionisi F, Guarneri A, Dell’Acqua V, Leonardi M, Niespolo R, Macchia G et al. Radiotherapy in the multidisciplinary treatment of liver cancer: a survey on behalf of the Italian Association of Radiation Oncology. Radiol Med. 2016 [cited 2023 Apr 2];121:735–43. https://pubmed.ncbi.nlm.nih.gov/27255503/.

Mantel F, Flentje M, Guckenberger M. Stereotactic body radiation therapy in the re-irradiation situation - a review. Radiat Oncol. 2013;8.

Willmann J, Adilovic S, Badra EV, Christ SM, Ahmadsei M, Tanadini-Lang S et al. Repeat stereotactic body radiotherapy for oligometastatic disease. Radiother Oncol. 2023 [cited 2023 Apr 23];184:109671. http://www.thegreenjournal.com/article/S0167814023002098/fulltext.

Andratschke N, Willmann J, Appelt AL, Alyamani N, Balermpas P, Baumert BG et al. Policy Review European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making.

Gomez D, Tang C, Zhang J. al. et. Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–8.

Article  PubMed  Google Scholar 

Shen Y, Zhu X, Cao F, Xie H, Ju X, Cao Y et al. Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases. Front Oncol. 2021 [cited 2022 Aug 31];11. https://pubmed.ncbi.nlm.nih.gov/34796108/.

Ceylan C, Hamacl A, Ayata H, Berberoglu K, Klllç A, Güden M, et al. Re-irradiation of Locoregional NSCLC recurrence using robotic stereotactic body Radiotherapy. Oncol Res Treat. 2017;40:207–14.

Article  CAS  PubMed  Google Scholar 

Kennedy WR, Gabani P, Nikitas J, Robinson CG, Bradley JD, Roach MC. Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT. Radiother Oncol. 2020 [cited 2022 Jun 22];142:230–5. https://pubmed.ncbi.nlm.nih.gov/31481272/.

Kimura T, Takeda A, Tsurugai Y, Kawano R, Doi Y, Oku Y et al. A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2020 [cited 2022 Sep 26];108:1265–75. https://pubmed.ncbi.nlm.nih.gov/32712256/.

Sumita K, Harada H, Asakura H, Ogawa H, Onoe T, Murayama S et al. Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study. Radiat Oncol. 2016;11.

John C, Dal Bello R, Andratschke N, Guckenberger M, Boda-Heggemann J, Gkika E et al. In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO). Sci Rep. 2021 [cited 2022 Jun 22];11. https://pubmed.ncbi.nlm.nih.gov/33633130/.

Greto D, Livi L, Bonomo P, Masi L, Detti B, Meattini I et al. Cyberknife stereotactic radiosurgery for the re-irradiation of brain lesions: a single-centre experience. Radiol Med. 2014 [cited 2023 Apr 2];119:721–6. https://pubmed.ncbi.nlm.nih.gov/24469988/.

Boldrini L, Romano A, Chiloiro G, Corradini S, De Luca V, Verusio V et al. Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis. Radiat Oncol. 2023 [cited 2023 Oct 11];18. https://pubmed.ncbi.nlm.nih.gov/37218005/.

Lo CH, Huang WY, Lin KT, Lin MJ, Lin TP, Jen YM. Repeated stereotactic ablative radiotherapy using CyberKnife for patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2014 [cited 2022 Sep 17];29:1919–25. https://pubmed.ncbi.nlm.nih.gov/25041220/.

Kimura T, Takeda A, Tsurugai Y, Kawano R, Doi Y, Oku Y, et al. A multi-institutional retrospective study of repeated stereotactic body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2020;108:1265–75.

Article  PubMed  Google Scholar 

Sun J, Ouyang C, Chang X, Zhang A, Wang Q, Li W et al. Repeated CyberKnife stereotactic body radiation therapy in hepatocellular carcinoma. Radiat Oncol. 2020;15.

McDuff SGR, Remillard KA, Zheng H, Raldow AC, Wo JY, Eyler CE, et al. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018;8:414–21.

Article  PubMed  Google Scholar 

Doty DG, Chuong MD, Gomez AG, Bryant J, Contreras J, Romaguera T et al. Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report. Med Dosim. 2021 [cited 2022 Jun 30];46. https://pubmed.ncbi.nlm.nih.gov/34120803/.

Caravatta L, Fiorica F, Rosa C, Boldrini L, Alitto AR, Nardangeli A et al. Role of upper abdominal reirradiation for gastrointestinal malignancies: a systematic review of cumulative dose, toxicity, and outcomes on behalf of the Re-irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Strahlentherapie Und Onkol. 2020;196.

Corradini S, Alongi F, Andratschke N, Belka C, Boldrini L, Cellini F et al. MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiat Oncol. 2019 [cited 2022 Sep 3];14. https://pubmed.ncbi.nlm.nih.gov/31167658/.

Dhont J, Vandemeulebroucke J, Cusumano D, Boldrini L, Cellini F, Valentini V et al. Multi-object tracking in MRI-guided radiotherapy using the tracking-learning-detection framework. Radiother Oncol. 2019 [cited 2019 Jun 8];138:25–9. http://www.ncbi.nlm.nih.gov/pubmed/31136959.

Corradini S, Alongi F, Andratschke N, Azria D, Bohoudi O, Boldrini L et al. ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. Radiother Oncol. 2021 [cited 2022 Oct 6];159:146–54. https://pubmed.ncbi.nlm.nih.gov/33775715/.

Boldrini L, Corradini S, Gani C, Henke L, Hosni A, Romano A et al. MR-Guided Radiotherapy for Liver Malignancies. Front Oncol. 2021 [cited 2022 Oct 6];11:616027. http://www.ncbi.nlm.nih.gov/pubmed/33869001.

Yoon SM, Luterstein E, Chu FI, Cao M, Lamb J, Agazaryan N et al. Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis. Cancer Med. 2021 [cited 2022 Jun 22];10:5897. /pmc/articles/PMC8419771/.

Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018;126:519–26.

Article  PubMed  Google Scholar 

Boldrini L, Romano A, Mariani S, Cusumano D, Catucci F, Placidi L et al. MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach. J Cancer Res Clin Oncol. 2021 [cited 2023 Apr 2];147:2057–68. https://pubmed.ncbi.nlm.nih.gov/33398447/.

Placidi L, Cusumano D, Boldrini L, Votta C, Pollutri V, Antonelli MV et al. Quantitative analysis of MRI-guided radiotherapy treatment process time for tumor real‐time gating efficiency. J Appl Clin Med Phys. 2020 [cited 2022 Oct 5];21:70. /pmc/articles/PMC7701108/.

Klüter S. Technical design and concept of a 0.35 T MR-Linac. Clin Transl Radiat Oncol. 2019 [cited 2023 Apr 27];18:98–101. https://pubmed.ncbi.nlm.nih.gov/31341983/.

Dhont J, Vandemeulebroucke J, Cusumano D, Boldrini L, Cellini F, Valentini V, et al. Multi-object tracking in MRI-guided radiotherapy using the tracking-learning-detection framework. Radiother Oncol. 2019;138:25–9.

Article  PubMed  Google Scholar 

Placidi L, Nardini M, Cusumano D, Boldrini L, Chiloiro G, Romano A et al. VMAT-like plans for magnetic resonance guided radiotherapy: Addressing unmet needs. Phys Medica. 2021 [cited 2023 Jan 23];85:72–8. http://www.physicamedica.com/article/S1120179721001836/fulltext.

Diez P, Hanna GG, Aitken KL, van As N, Carver A, Colaco RJ et al. UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. Clin Oncol (R Coll Radiol). 2022 [cited 2022 Sep 19];34:288–300. https://pubmed.ncbi.nlm.nih.gov/35272913/.

Gerhard SG, Palma DA, Arifin AJ, Louie AV, Li GJ, Al-Shafa F, et al. Organ at risk dose constraints in SABR: a systematic review of active clinical trials. Pract Radiat Oncol. 2021;11:e355–65.

Article  PubMed  Google Scholar 

Das S, Patro K, Mukherji A. Recovery and tolerance of the organs at risk during re-irradiation. J Curr Oncol. 2018;1:23.

Article  Google Scholar 

McKenzie E, Zhang L, Zaki P, Chan S, Ganesh V, Razvi Y, et al. Re-analysis of symptom clusters in advanced cancer patients attending a palliative outpatient radiotherapy clinic. Ann Palliat Med. 2019;8:140–9.

Article  PubMed  Google Scholar 

Votta C, Cusumano D, Boldrini L, Dinapoli N, Placidi L, Turco G et al. Delivery of online adaptive magnetic resonance guided radiotherapy based on isodose boundaries. Phys Imaging Radiat Oncol. 2021 [cited 2023 Jan 22];18:78. /pmc/articles/PMC8254198/.

National Cancer Institute (U.S.). (2010). Common terminology criteria for adverse events: (ctcae) (V4.03 ed.). U.S. Department of Health and Human Services. Retrieved December 5 2022 from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14. [cited 2022 Dec 5]. https://www.worldcat.org/it/title/common-terminology-criteria-for-adverse-events-ctcae/oclc/717514417.

Lee DS, Woo JY, Kim JW, Seong J. Re-Irradiation of Hepatocellular Carcinoma: Clinical Applicability of Deformable Image Registration. Yonsei Med J. 2016 [cited 2022 Dec 11];57:41–9. https://pubmed.ncbi.nlm.nih.gov/26632381/.

Gkika E, Strouthos I, Kirste S, Adebahr S, Schultheiss M, Bettinger D, et al. Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlentherapie Und Onkol. 2019;195:246–53.

Article  Google Scholar 

Seol SW, Yu J, Il, Park HC, Lim DH, Oh D, Noh JM et al. Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma. Radiat Oncol J. 2015 [cited 2022 Dec 11];33:276–83. https://pubmed.ncbi.nlm.nih.gov/26756027/.

Miften M, Vinogradskiy Y, Moiseenko V, Grimm J, Yorke E, Jackson A, et al. Radiation dose-volume effects for Liver SBRT. Int J Radiat Oncol. 2021;110:196–205.

Article  Google Scholar 

Dell’Acqua V, Surgo A, Kraja F, Kobiela J, Zerella MA, Spychalski P et al. Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions. Clin Exp Metastasis. 2019 [cited 2022 Dec 14];36:331–42. https://pubmed.ncbi.nlm.nih.gov/31165360/.

Lin Q, Zhou N, Zhu X, Lin J, Fang J, Gu F et al. Outcomes of SBRT for lung oligo-recurrence of non-small cell lung cancer: a retrospective analysis. J Radiat Res. 2022 [cited 2022 Dec 15];63:272–80. https://pubmed.ncbi.nlm.nih.gov/34958672/.

Rezaeijo SM, Hashemi B, Mofid B, Bakhshandeh M, Mahdavi A, Hashemi MS. The feasibility of a dose painting procedure to treat prostate cancer based on mpMR images and hierarchical clustering. Radiat Oncol. 2021 [cited 2024 Apr 14];16. https://pubmed.ncbi.nlm.nih.gov/34544468/.

Khanfari H, Mehranfar S, Cheki M, Mohammadi Sadr M, Moniri S, Heydarheydari S et al. Exploring the efficacy of multi-flavored feature extraction with radiomics and deep features for prostate cancer grading on mpMRI. BMC Med Imaging. 2023 [cited 2024 Apr 14];23. https://pubmed.ncbi.nlm.nih.gov/37993801/.